This Seattle Lymphoma Rounds will be a virtual program to deliver live professional education programming during the coronavirus (COVID-19) outbreak. This program will still provide a forum for local practicing physicians from academic and community medical centers to meet and address issues specific to the diagnosis and treatment of their lymphoma patients. You will be able to tune in over the phone or online.  Please continue to check this page for updates. For updates, please ensure you are subscribed to receive emails from the Lymphoma Research Foundation

For LRF’s official statement on COVID-19 and LRF programs and events, please click here.

Virtual Lymphoma Rounds: Seattle

Date:  Wednesday, April 28, 2021
7:00 PM – 8:45 PM PT

VIRTUAL PROGRAM – This is a virtual Zoom event, accessible online and over the phone. Access instructions will be emailed after registration. If you are new to Zoom, learn more here: How-Do-I-Join-or-Test-My-Computer-Audio

This program is free for healthcare professionals; however, pre-registration is required.

Please note: Only representatives from supporting pharmaceutical companies are invited to register. If your company is interested in becoming a Lymphoma Rounds supporter please contact Sarah Quinlan, LRF, at squinlan@lymphoma.orgVirtual Exhibit opportunities are available.

Companies that have secured a national exhibit sponsorship for Lymphoma Rounds must still rsvp by emailing Sarah Quinlan (squinlan@lymphoma.org) at least one week before the program to confirm their attendance.

To Register

VIRTUAL PROGRAM – This is a virtual Zoom event, accessible online and over the phone. Access instructions will be emailed after registration. If you are new to Zoom, learn more here: How-Do-I-Join-or-Test-My-Computer-Audio

ABOUT THE PROGRAM
The Lymphoma Rounds program provides a forum for local practicing physicians from academic and community medical centers to meet on a regular basis and address issues specific to the diagnosis and treatment of their lymphoma patients. Physicians share best practices and learn the latest information on new therapies and advances in the management of lymphoma through interactive case studies presented by lymphoma experts in the local area.

At the conclusion of this educational activity, the participant should be better able to:

  • Summarize the latest developments in lymphoma diagnosis, treatment and management.
  • Apply best practices for treating lymphoma patients.
  • Inform patients about potential clinical trial opportunities.
  • Establish a network of health care professionals who work with lymphoma patients.

This is the second program in the 2020-21 Seattle Rounds series.

Seattle Lymphoma Rounds Steering Committee

Kaiser Permanente Washington
Eric Chen, MD, PhD
The Polyclinic
Sherry Hu, MD, PhD
Swedish Medical Center
Krish Patel, MD
University of Washington
Paul S. Martin, MD (chair)
The University of Washington/Fred Hutchinson Cancer Research Center
Stephen D. Smith, MD
Virginia Mason Medical Center
David Aboulafia, MD

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Lymphoma Research Foundation and University of Nebraska Medical Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Statement

The University of Nebraska Medical Center designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit (s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Sponsors
Lymphoma Research Foundation and the University of Nebraska Medical Center.

This activity is supported by educational grants from:
Acrotech Biopharma LLC, AstraZeneca, Bristol Myers Squibb, BTG International, Inc., Genentech, A Member of the Roche Group; Karyopharm Therapeutics, Kite Pharma, a Gilead Company; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Seagen and TG Therapeutics, Inc.